A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag279 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Suzanne Jones und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville, TN 37203, United States. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation Medicine.
Abstract (Originalsprache)
Background
Initial studies have shown improved outcomes in patients receiving cancer therapies matched to their molecular alterations. To improve the chances of finding a therapeutic match for patients, this study evaluated the preliminary antitumor activity of 3 commercially available multitargeted agents in the United States, regorafenib, afatinib, and cabozantinib.
Methods
In this phase II trial, patients who did not benefit from first-line treatment for non-small cell lung cancer (NSCLC), upper aerodigestive tract cancers, non-colon gastrointestinal cancers, and urothelial carcinoma underwent next-generation sequencing to identify actionable genomic alterations. Eligible patients, based on identified mutations deemed treatable by regorafenib, cabozantinib, or afatinib, were enrolled to receive matched targeted therapies. Outcomes were monitored via Response Evaluation Criteria in Solid Tumors criteria, with dose modifications per National Cancer Institute Common Terminology Criteria for Adverse Events, v4.03 guidelines for adverse events (AEs).
Results
One hundred patients with metastatic cancers were enrolled across tumor types. Median treatment durations were 12 weeks (regorafenib), 10.7 weeks (afatinib), and 24.1 weeks (cabozantinib). The overall objective response rate was 7.0%, with 1 complete response and 8 partial responses. The clinical benefit rate, including responses and stable disease >6 months, was 16.0%. Median progression-free survival ranged from 1.9 months for urothelial carcinoma to 3.2 months for NSCLC. Toxicities were common for all medications; for regorafenib, 90.7% of patients had AEs (50% Grade 3/4); for afatinib, 86% of patients had AEs (54% Grade 3/4); for cabozantinib, 100% of patients had AEs (36% Grade 3/4). The most common AEs were diarrhea, fatigue, nausea, decreased appetite, and stomatitis.
Conclusions
Regorafenib, afatinib, and cabozantinib had modest effects when used as molecularly matched targeted therapies in patients with NSCLC, upper aerodigestive tract cancers, non-colon gastrointestinal cancers, and urothelial carcinoma in the second-line setting. Future research could examine more precise matching of therapies to genomic alterations and evaluate combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarah Cannon Research Institute, Nashville, TN 37203, United States.
- Sarah Cannon Research Institute at HealthOne, Denver, CO 80218, United States.
- HCA Midwest Kansas City, Kansas City, KS 64132, United States.
- Tennessee Oncology, PLLC, Nashville, TN 37203, United States.
- Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Florida Cancer Specialists and Research Institute East, Wellington, FL 33414, United States.
ORCID-Profile: Howard A Burris
Förderung
- Foundation Medicine
Zitieren
APA
Jones, S., Falchook, G., Graff, S., Arrowsmith, E., Kilari, D., Gersten, T. A., Hussein, M., Percent, I., & Burris, H. A. (2026). A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting. The Oncologist. https://doi.org/10.1093/oncolo/oyag279
Vancouver
Jones S, Falchook G, Graff S, Arrowsmith E, Kilari D, Gersten TA, et al. A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting. The Oncologist. 2026. doi:10.1093/oncolo/oyag279
BibTeX
@article{Jones2026,
author = {Jones, Suzanne and Falchook, Gerald and Graff, Stephanie and Arrowsmith, Edward and Kilari, Deepak and Gersten, Todd A and Hussein, Maen and Percent, Ivor and Burris, Howard A},
title = {A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag279}
}
EUVIMED